Literature DB >> 9151222

Chemistry and biology of some low molecular weight boron compounds for boron neutron capture therapy.

S Sjöberg1, J Carlsson, H Ghaneolhosseini, L Gedda, T Hartman, J Malmquist, C Naeslund, P Olsson, W Tjarks.   

Abstract

Boronated DNA targeting agents are especially attractive candidates for BNCT because they may deliver boron-10 to the nuclei of tumor cells. Numerous boron-containing analogs have been synthesized and some have shown promising results in initial biological tests. One of the most challenging tasks in this special field of research remains the finding of suitable targeting strategies for the selective delivery of boron rich DNA-intercalator/alkylator to tumor cells. Synthetic and biological studies of boron compounds suitable for DNA-binding are reviewed. The amino acid p-boronophenylalanine (BPA) is presently of considerable clinical interest. Other boronated amino acids might also be candidates for BNCT either per se, as part of part of tumor-seeking peptides or conjugated to targeting macromolecules. A large number of boronated L- and D-amino acids with varying liphophicility and sterical requirements are now available for evaluation. Recent synthetic and biological studies of aromatic boronoamino acids, carboranylamino acids and carboranyl amines are also reviewed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9151222     DOI: 10.1023/a:1005756929011

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  25 in total

1.  Analytical calculation of boron- 10 dosage in cell nucleus for neutron capture therapy.

Authors:  T Kobayashi; K Kanda
Journal:  Radiat Res       Date:  1982-07       Impact factor: 2.841

2.  New compounds: organoboron derivatives of tetracyclines I: synthesis of carboxamido derivative of tetracycline with perhydro-2-phenyl-1,3,6,2-dioxazaborocine.

Authors:  C W Roscoe; J W Phillips; W C Gillchriest
Journal:  J Pharm Sci       Date:  1977-10       Impact factor: 3.534

3.  Carboranes. 3. Boron-containing acridines.

Authors:  M A Davis; A H Soloway
Journal:  J Med Chem       Date:  1967-07       Impact factor: 7.446

4.  Carboranes. I. Nitrogen mustards.

Authors:  A H Soloway; D N Butler
Journal:  J Med Chem       Date:  1966-05       Impact factor: 7.446

5.  Penetration and binding of L- and D-carboranylalanine in human melanoma spheroids.

Authors:  O A Pettersson; P Olsson; P Lindström; S Sjöberg; J Carlsson
Journal:  Melanoma Res       Date:  1993-10       Impact factor: 3.599

6.  Carboranyl peptide-antibody conjugates for neutron-capture therapy: preparation, characterization, and in vivo evaluation.

Authors:  R J Paxton; B G Beatty; A Varadarajan; M F Hawthorne
Journal:  Bioconjug Chem       Date:  1992 May-Jun       Impact factor: 4.774

7.  Radiation dose heterogeneity in receptor and antigen mediated boron neutron capture therapy.

Authors:  T Hartman; J Carlsson
Journal:  Radiother Oncol       Date:  1994-04       Impact factor: 6.280

Review 8.  Boron neutron capture therapy for cancer. Realities and prospects.

Authors:  R F Barth; A H Soloway; R G Fairchild; R M Brugger
Journal:  Cancer       Date:  1992-12-15       Impact factor: 6.860

Review 9.  Present status of boron neutron capture therapy.

Authors:  J Carlsson; S Sjöberg; B S Larsson
Journal:  Acta Oncol       Date:  1992       Impact factor: 4.089

10.  Strategy for boron neutron capture therapy against tumor cells with over-expression of the epidermal growth factor-receptor.

Authors:  J Carlsson; L Gedda; C Grönvik; T Hartman; A Lindström; P Lindström; H Lundqvist; A Lövqvist; J Malmqvist; P Olsson
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-08-30       Impact factor: 7.038

View more
  2 in total

1.  Accumulation of boron in human malignant glioma cells in vitro is cell type dependent.

Authors:  Maria Dahlström; Jacek Capala; Peter Lindström; Ake Wasteson; Annelie Lindström
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

Review 2.  Ligand liposomes and boron neutron capture therapy.

Authors:  Jörgen Carlsson; Erika Bohl Kullberg; Jacek Capala; Stefan Sjöberg; Katarina Edwards; Lars Gedda
Journal:  J Neurooncol       Date:  2003 Mar-Apr       Impact factor: 4.130

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.